Login to Your Account



Aicuris banks $122M milestone on FDA nod for letermovir; EMA decision imminent

By Cormac Sheridan
Staff Writer

Friday, November 10, 2017

DUBLIN – Aicuris Anti-infective Cures GmbH is banking a €105 million (US$122 million) milestone from Merck & Co. Inc. on the back of an FDA approval of letermovir for preventing cytomegalovirus (CMV) reactivation in seropositive adults undergoing allogeneic hematopoietic stem cell transplant (HSCT). There could be cause for a double celebration shortly, as the drug is also up for decision at the EMA's Committee for Human Medicinal Products (CHMP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription